Genomic SNP array as a gold standard for prenatal diagnosis of foetal ultrasound abnormalities by Srebniak, M.I. (Malgorzata) et al.
SHORT REPORT Open Access
Genomic SNP array as a gold standard for
prenatal diagnosis of foetal ultrasound
abnormalities
Malgorzata I Srebniak1*, Marjan Boter1, Gretel O Oudesluijs1, Titia Cohen-Overbeek2, Lutgarde CP Govaerts1,
Karin EM Diderich1, Renske Oegema1, Maarten FCM Knapen2, Ingrid MBH van de Laar1, Marieke Joosten1,
Diane Van Opstal1 and Robert-Jan H Galjaard1
Abstract
Background: We have investigated whether replacing conventional karyotyping by SNP array analysis in cases of
foetal ultrasound abnormalities would increase the diagnostic yield and speed of prenatal diagnosis in clinical
practice.
Findings/results: From May 2009 till June 2011 we performed HumanCytoSNP-12 array (HCS) (http://www.Illumina.
com) analysis in 207 cases of foetal structural abnormalities. HCS allows detecting unbalanced genomic
abnormalities with a resolution of about 150/200 kb. All cases were selected by a clinical geneticist after excluding
the most common aneuploidies by RAD (rapid aneuploidy detection). Pre-test genetic counselling was offered in
all cases.
In 24/207 (11,6%) foetuses a clinically relevant genetic abnormality was detected. Only 8/24 abnormalities would
have been detected if only routine karyotyping was performed. Submicroscopic abnormalities were found in 16/
207 (7,7%) cases. The array results were achieved within 1-2 weeks after amniocentesis.
Conclusions: Prenatal SNP array testing is faster than karyotyping and allows detecting much smaller aberrations
(~0.15 Mb) in addition to the microscopic unbalanced chromosome abnormalities detectable with karyotyping (~ >
5 Mb). Since karyotyping would have missed 66% (16/24) of genomic abnormalities in our cohort, we propose to
perform genomic high resolution array testing assisted by pre-test counselling as a primary prenatal diagnostic test
in cases of foetal ultrasound abnormalities.
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Findings
Array based diagnosis of foetal unbalanced chromosome
abnormalities has been successfully employed on prenatal
material [1,2]. However, the standard cytogenetic prenatal
diagnosis often still includes time-consuming karyotyping
followed by targeted FISH or MLPA analysis when a sub-
microscopic abnormality is suspected. Although foetal
anomalies are a strong indication of a genetic abnormality,
chromosome analysis can only detect aberrations in about
one fifth of cases [3]. In 1999-2010 we tested 3076 cases of
foetuses with abnormal ultrasound findings and 21,7%
(665) had an abnormal karyotype (including triploidy, tris-
omy 13, 18, 21 and aneuploidies of X and Y chromosome).
Prenatal genetic diagnosis after ultrasound detection of
foetal abnormalities requires a fast diagnostic technique.
A technique with higher resolution than karyotyping is
preferable to avoid the need of subsequent microdele-
tion/microduplication testing. Implementing rapid
microarray technology in routine prenatal diagnosis will
allow the detection of unbalanced chromosomal abnorm-
alities in a shorter period of time with much better reso-
lution than conventional karyotyping [4].
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ultrasound abnormalities would increase the diagnostic
yield and speed of prenatal diagnosis in clinical practice.
In order to implement SNP array analysis we first stu-
died its limitations. Array technology cannot detect true
balanced chromosome abnormalities and non-euchro-
matic small supernumerary marker chromosomes (sSMC).
Since these sSMCs are assumed to be benign in absence of
uniparental disomy (UPD), detectable with SNP arrays [5],
we further concentrated on balanced abnormalities. It is
known that the prevalence of de novo balanced abnormal-
ities in prenatal cohorts is low. 66 cases of apparently de
novo balanced abnormalities were found in a cohort of
76952 samples by Warburton 1984 [6]. We have investi-
gated the prevalence of a de novo reciprocal apparently
balanced translocations in the population tested in our
laboratory. In 1999-2010, of the total 23,357 cases, 3076
were karyotyped because of (an) ultrasound abnormality
(ies). Only 2/3076 foetuses had a de novo apparently
balanced reciprocal translocation (which is concordant to
the data presented by Warburton 1984 [6]). These 2 cases
were retrospectively tested with a HumanCytoSNP-12
array (HCS, 150 kb resolution). The first case (foetus with
single umbilical artery, increased NT and a small sto-
mach), who had a de novo apparently balanced t(1;6)(p31;
q15) appeared to have a 3,8 Mb deletion at 1p31 and addi-
tionally a 3,1 Mb duplication in the 22q11 DiGeorge criti-
cal region. The second case (foetus with choroid plexus
cysts and gastroschisis), who had an apparently balanced
de novo t(9;20)(p12;q13.1), appeared to be truly balanced,
when tested with HCS. Based on these data one can
assume that the risk of a true balanced reciprocal translo-
cation in foetuses with an ultrasound anomaly is very low:
~1:3000.
Low level mosaicism was another of our concerns in
considering a SNP array as a primary diagnostic tool.
Traditional karyotyping can exclude 26% mosaicism with
95% confidence when 10 cells are investigated, which is
common practice in the Netherlands [7]. Recently, it was
shown that Illumina SNP array can detect 10% of abnor-
mal cells or even less if mosaicism involves the introduc-
tion of a new haplotype [8].
Although CGH array has also been successfully imple-
mented into prenatal diagnosis [9], as we described
before [4], we have chosen Illumina SNP array mainly
because it requires only 50 ng DNA, long culturing can
be avoided and rapid results can be provided within
72 hours.
From May 2009 till June 2011 723 cases of foetal ultra-
sound abnormalities were referred to our laboratory for
prenatal cytogenetic testing. RAD (rapid aneuploidy detec-
tion) by using FISH, MLPA or QF-PCR was performed on
all cases of ultrasound abnormalities. In 143 of 723
(19,7%) cases trisomy 13, 18, 21 or sex-chromosomal
aneuploidy was found. In 12 of 723 (1,6%) triploidy was
detected. After excluding the most common aneuploidies
and triploidy by RAD the gynaecologists referred the
patients to a clinical geneticist for pre-test genetic counsel-
ling and genomic array testing. After pre-test counselling
(performed as described before [4]) clinical geneticists
selected 207 cases for high resolution SNP array testing
(including the 61 pilot cases that were previously pub-
lished [4]).
In the first cases, a genomic array was requested after
the karyotype appeared to be normal, later on both array
and karyotyping were simultaneously performed to com-
pare the performance and reporting time. Since September
2010 we perform array testing as a stand-alone test.
Foetal and parental DNA were simultaneously tested to
exclude familial variations. The parental DNA was not
always necessary to interpret the foetal array data, but to
avoid the subsequent testing and speed up the analysis it
was performed simultaneously to the foetal array. The
array profiles were analyzed in UCSC built Hg18 (Human
Mar. 2006 (NCBI36/hg18) Assembly) by using Nexus
Copy Number 5.0 software (BioDiscovery) [4].
After excluding the most common trisomies and tri-
ploidy by RAD 207 cases were tested with HCS. In 24/207
(11,6%) foetuses a clinically relevant genetic abnormality
was detected by genomic array (Additional file 1). A CNV
was classified as clinically relevant if it was associated with
a known disease or genetic syndrome or associated with
an increased risk for such a disease or genetic syndrome.
In 8/207 (3,7%) cases microscopically detectable abnorm-
ality was found. Submicroscopic abnormalities were found
in 16/207 (7,7%) cases with foetal ultrasound abnormal-
ities. These results are concordant to the data reported
before (9% (10/106) [10], 10% (5/50) [11], 8.2% (4/49)
[12]).
The use of SNP array technology instead of karyotyp-
ing increased the diagnostic yield from ~25% (19,7%
common aneuploidies, 1,6% triploidy, 3,9% chromoso-
mal abnormalities that would have been detected by
karyotyping (8/207)) to ~33% (19,7% common aneuploi-
dies, 1,6% triploidy and 11,6% all abnormalities detected
by genomic array). However, the cases presented here,
were highly selected (by both gynaecologists and clinical
geneticists) and the percentage could change if the array
testing is offered for all foetuses with ultrasound
abnormalities. The reporting time was shortened from
2-3 weeks (karyotyping in AF in our center) to ≤ 1-2
weeks (array request on uncultured AF).
Only 8/16 submicroscopic abnormalities were larger
than 1 Mb. Therefore, we believe that array testing with
the resolution higher than 1 Mb is required for cases
with foetal ultrasound abnormalities.
In 5 cases (cases 13-16 and 20 - Additional file 1) an
unexpected abnormality was found. A CNV associated
with an increased risk for a health condition was found.
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These CNVs are probably not related to the ultrasound
abnormality found in the foetus and may not be suffi-
cient to cause a phenotype. However it is known that
these genomic regions have been hypothesized to be
susceptibility loci. Incomplete penetrance or variable
expressivity might be the explanation of the phenotype
variability. The abnormal phenotype might also be
caused by co-existence of an additional genetic, epige-
netic, or environmental factor [13]. In such cases the
correlation with the prenatal phenotype is extremely dif-
ficult as no large patients’ groups with such CNVs were
prenatally studied or described. Such finding could be
problematic, however in our department the possibility
of finding such risk factors is discussed with the patients
during the pre-test counselling [4]. Whether information
about risk factors was released to the patient depends
on her own choice after pre-test counselling.
In 32% of our cases an unclassified variant (UV) was
found. A copy number variant (CNV) was classified as an
UV if it was not associated with a known human abnormal
phenotype and was not seen in more than 3 healthy indivi-
duals in DGV http://projects.tcag.ca/variation/, CHOP
database (http://cnv.chop.edu) or in our local databases.
About 85% of these unclassified variants were inherited
from a healthy parent and therefore considered to be a
(private) familial polymorphism. According to our policy,
results of unknown clinical significance were not revealed
to the parents (during the pre-test counselling the patient
consent was obtained and the consequences were
discussed).
After evaluation of the advantages and disadvantages
of the SNP array technology, its validation in our labora-
tory [4] and a year experience, we decided to replace
karyotyping by a HumanCytoSNP-12 array (HCS) in
cases of foetal ultrasound abnormalities for several
reasons:
• HCS detects all clinically relevant unbalanced chro-
mosome abnormalities also detected by karyotyping
(including triploidy)
• HCS has a 25-50× higher resolution than karyotyp-
ing and therefore allows genome wide screening for
microdeletions and microduplications.
• It can be employed on uncultured tissue (only 50 ng
DNA is required)
• It is faster than karyotyping (in most cases results
can be achieved within one week)
• The risk of undetected low level mosaicism is likely
to be smaller than with conventional karyotyping [8,14],
which is supported by our case 7 (Additional file 1:
mosaic trisomy 8 (~10%) that has been missed by
karyotyping).
SNP array analysis is now the preferred cytogenetic
technique in cases of foetal ultrasound abnormalities
after exclusion of the most common aneuploidies and
triploidy. It has already been shown that the diagnostic
yield can be increased by 3,6% in samples with normal
karyotype regardless of the indication [15]. Since karyo-
typing would have missed 66% (16/24) of genomic
abnormalities in our cohort, we propose to perform
genomic high resolution array testing assisted by pre-
test counselling as a primary prenatal diagnostic test
after amniocentesis in cases of foetal ultrasound
abnormalities.
Additional material
Additional file 1: Table 1. Summary of clinical significant abnormalities
detected by SNP array in 24 of 207 cases.
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